Brilinta Value-Based Contract With UPMC Incorporates Two-Sided Risk
Executive Summary
AstraZeneca and UPMC Health Plan have signed a value-based contract for Brilinta linked to cardiovascular outcomes, with UPMC agreeing to pay more if the drug outperforms expectations.